The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
Hyperphosphatemia is common in the peritoneal dialysis population. Current strategies are
insufficient to optimize phosphorus control. Animal studies have shown niacinamide, a form of
vitamin B, to reduce phosphate uptake by the rat small intestine. Our trial investigates the
use of niacinamide, in addition to standard phosphorus lowering strategies, to reduce plasma
phosphorus levels in peritoneal dialysis patients versus placebo.